F
0.460
-0.12 (-21.35%)
| Penutupan Terdahulu | 0.585 |
| Buka | 0.566 |
| Jumlah Dagangan | 36,531,606 |
| Purata Dagangan (3B) | 4,887,085 |
| Modal Pasaran | 70,551,144 |
| Harga / Jualan (P/S) | 32.19 |
| Harga / Buku (P/B) | 1.86 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| Margin Operasi (TTM) | -161,246.67% |
| EPS Cair (TTM) | -1.94 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -57.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 963.53% |
| Nisbah Semasa (MRQ) | 2.50 |
| Aliran Tunai Operasi (OCF TTM) | -78.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -47.87 M |
| Pulangan Atas Aset (ROA TTM) | -49.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -196.81% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Fractyl Health, Inc. | Menurun | Menurun |
AISkor Stockmoo
1.0
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 1.00 |
|
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 4.84% |
| % Dimiliki oleh Institusi | 82.39% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Hcc Manager Llc | 30 Sep 2025 | 4,673,871 |
| M28 Capital Management Lp | 30 Sep 2025 | 1,856,117 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 8.00 (Canaccord Genuity, 1,639.13%) | Beli |
| 8.00 (HC Wainwright & Co., 1,639.13%) | Beli | |
| Median | 8.00 (1,639.13%) | |
| Rendah | 2.00 (Morgan Stanley, 334.78%) | Pegang |
| Purata | 6.00 (1,204.35%) | |
| Jumlah | 2 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 1.23 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 30 Jan 2026 | 2.00 (334.78%) | Pegang | 0.460 |
| HC Wainwright & Co. | 02 Dec 2025 | 8.00 (1,639.13%) | Beli | 1.84 |
| Canaccord Genuity | 21 Nov 2025 | 8.00 (1,639.13%) | Beli | 1.40 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |